G1 Therapeutics (GTHX) Set to Announce Earnings on Thursday

G1 Therapeutics (NASDAQ:GTHX) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, August 8th. Analysts expect G1 Therapeutics to post earnings of ($0.17) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

G1 Therapeutics Stock Up 7.6 %

Shares of NASDAQ:GTHX opened at $4.25 on Wednesday. The company has a quick ratio of 2.55, a current ratio of 2.94 and a debt-to-equity ratio of 1.34. G1 Therapeutics has a 52-week low of $1.08 and a 52-week high of $6.14. The company has a 50 day moving average of $3.10 and a two-hundred day moving average of $3.63. The company has a market capitalization of $222.19 million, a price-to-earnings ratio of -6.85 and a beta of 1.53.

Analyst Ratings Changes

Several equities analysts have recently commented on GTHX shares. HC Wainwright reduced their target price on G1 Therapeutics from $9.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, June 25th. Needham & Company LLC reduced their target price on G1 Therapeutics from $12.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, June 25th. Finally, Wedbush reiterated an “outperform” rating and set a $3.00 target price (down from $5.00) on shares of G1 Therapeutics in a research note on Monday, June 24th.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.